Association between serum osteoprotegerin level and mortality in kidney transplant recipients ‐ a prospective observational cohort study
- 19 February 2021
- journal article
- research article
- Published by Frontiers Media SA in Transplant International
- Vol. 34 (5) , 844-854
Abstract
Paradoxically, higher serum levels of osteoprotegerin (OPG: a vascular calcification inhibitor) have been associated with increased arterial stiffness, risk of cardiovascular disease and all‐cause mortality. A few studies reported that post‐transplant OPG levels are associated with mortality in kidney transplant (KT) recipients. In this study, this association was assessed in a cohort of prevalent KT recipients, adjusting for previously untested potential confounders, including fibroblast growth factor 23 (FGF23) and interleukin 6 (IL‐6). Socio‐demographic and clinical parameters, medical and transplant history, and laboratory data were collected from 982 prevalent KT recipients. The association between serum OPG and all‐cause mortality over a 6‐year follow‐up period was examined using Kaplan‐Meier survival curves and multivariable adjusted Cox regression models. Participants with high serum OPG were more likely female, older, deceased donor KT recipients and have more comorbidity, lower eGFR, higher FGF23, higher IL‐6, and longer dialysis vintage. Each 1 pmol/L higher‐serum OPG level was associated with a 49% higher risk of mortality (hazard ratio (HR) [95% confidence interval (CI)]: 1.49 [1.40 – 1.61]). This association persisted after adjusting for confounders (HR [95% CI]: 1.20 [1.10 – 1.30]). In conclusion, serum OPG was associated with all‐cause mortality independent of several novel confounders in prevalent KT recipients.Keywords
Funding Information
- Egészségügyi Tudományos Tanács (206/09)
- Hungarian Scientific Research Fund (F‐68841, HUMAN‐MB08‐A‐81231)
This publication has 49 references indexed in Scilit:
- Update on fibroblast growth factor 23 in chronic kidney diseaseKidney International, 2012
- FGF23 induces left ventricular hypertrophyJournal of Clinical Investigation, 2011
- Fibroblast Growth Factor 23 and Risks of Mortality and End-Stage Renal Disease in Patients With Chronic Kidney DiseaseJAMA, 2011
- Elevated Fibroblast Growth Factor 23 is a Risk Factor for Kidney Transplant Loss and MortalityJournal of the American Society of Nephrology, 2011
- Inflammation in Renal TransplantationClinical Journal of the American Society of Nephrology, 2009
- Emerging Biomarkers for Evaluating Cardiovascular Risk in the Chronic Kidney Disease PatientClinical Journal of the American Society of Nephrology, 2008
- Early Posttransplant Serum Osteoprotegerin Levels Predict Long-Term (8-Year) Patient Survival and Cardiovascular Death in Renal Transplant PatientsJournal of the American Society of Nephrology, 2006
- Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD)Kidney International, 2005
- Osteoclast differentiation and activationNature, 2003
- Comparison of Mortality in All Patients on Dialysis, Patients on Dialysis Awaiting Transplantation, and Recipients of a First Cadaveric TransplantNew England Journal of Medicine, 1999